GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million. On January 15, the company announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received a Medical Device Registration Certificate from China's National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate complex solution product. The product, primarily composed of recombinant collagen and sodium hyaluronate, is intended for injection into the dermis to improve facial cheek smoothness. This product is the world's first implantable formulation of a recombinant collagen and sodium hyaluronate complex solution approved specifically for improving cheek smoothness, having officially passed a joint review by medical device and pharmaceutical regulatory authorities. CICC commented that it views the approval favorably, as it is expected to further expand the company's aesthetic product portfolio, demonstrating its leading technological R&D capabilities. The institution noted that the company is expected to steadily advance the product's launch, promotion, and market distribution, aiming to provide differentiated solutions through a diverse product mix, comprehensive channel network, and refined brand operations, thereby continuously strengthening its leading market position in the health and beauty sectors.